Cephalon’s Gabitril Marketing Scaled Back Pending Anxiety Trial Results
This article was originally published in The Pink Sheet Daily
Sales of Gabitril declined 36% to $15.7 mil. in the second quarter.
You may also be interested in...
A new bolded warning for Gabitril (tiagabine) highlighting the risk of non-epileptic seizures is needed because some doctors are using the drug off-label at higher than recommended levels, Cephalon Investor Relations Senior Director Chip Merritt said March 16 at the SG Cowen health care conference in Boston
Cephalon will turn over documents from 1998 to the present regarding "sales and promotional practices" for Provigil, Gabitril and Actiq.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.